Rapidly progressive glomerulonephritis pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(4 intermediate revisions by one other user not shown)
Line 2: Line 2:
{{Rapidly progressive glomerulonephritis}}
{{Rapidly progressive glomerulonephritis}}


{{CMG}}  
.{{CMG}} {{AE}} {{JSS}} {{SAH}}
 
==Overview==
Rapidly progressive glomerulonephritis is a disease of the kidney in which the [[renal function]] deteriorates in a few days. Atleast 50% reduction in [[Glomerular filtration rate|GFR]] occurs in RPGN in a few days to weeks. RPGN occurs from severe and fast damage to the [[GBM]] which results in [[Crescent Rising|crescent]] formation, the main pathological finding in RPGN. Injury can occur by anti [[GBM]] antibodies-type I RPGN, [[Immune complex]]- type II RPGN or  pauci immune RPGN(ANCAs)-type III RPGN. Crescents are present in the [[Bowman's capsule|Bowmans space]]. Light, immunofluoresnce and electron microscopy are used to diagnose RPGN.


==Overview==
==Pathophysiology==
==Pathophysiology==


Line 14: Line 16:
The key for the renal corpuscle figure is: A – [[Renal corpuscle]], B – [[Proximal tubule]], C – [[Distal convoluted tubule]], D – [[Juxtaglomerular apparatus]], 1. [[Basement membrane]] (Basal lamina), 2. [[Bowman's capsule]] – parietal layer, 3. [[Bowman's capsule]] – visceral layer, 3a. Pedicels (Foot processes from [[podocytes]]), 3b. [[Podocyte]], 4. [[Bowman's space]] (urinary space), 5a. [[Mesangium]] – Intraglomerular cell, 5b. [[Mesangium]] – Extraglomerular cell, 6. Granular cells ([[Juxtaglomerular cells]]), 7. [[Macula densa]], 8. [[Myocytes]] ([[smooth muscle]]), 9. [[Afferent arteriole]], 10. Glomerulus [[Capillaries]], 11. [[Efferent arteriole]].
The key for the renal corpuscle figure is: A – [[Renal corpuscle]], B – [[Proximal tubule]], C – [[Distal convoluted tubule]], D – [[Juxtaglomerular apparatus]], 1. [[Basement membrane]] (Basal lamina), 2. [[Bowman's capsule]] – parietal layer, 3. [[Bowman's capsule]] – visceral layer, 3a. Pedicels (Foot processes from [[podocytes]]), 3b. [[Podocyte]], 4. [[Bowman's space]] (urinary space), 5a. [[Mesangium]] – Intraglomerular cell, 5b. [[Mesangium]] – Extraglomerular cell, 6. Granular cells ([[Juxtaglomerular cells]]), 7. [[Macula densa]], 8. [[Myocytes]] ([[smooth muscle]]), 9. [[Afferent arteriole]], 10. Glomerulus [[Capillaries]], 11. [[Efferent arteriole]].


=== .Pathogenesis ===
=== Pathogenesis ===
* Rapidly progressive glomerulonephritis is a disease of the kidney in which the [[renal function]] deteriorates in a few days.
* Rapidly progressive glomerulonephritis is a disease of the kidney in which the [[renal function]] deteriorates in a few days<ref name="pmid3287904">{{cite journal| author=Couser WG| title=Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. | journal=Am J Kidney Dis | year= 1988 | volume= 11 | issue= 6 | pages= 449-64 | pmid=3287904 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3287904  }} </ref><ref name="pmid9507491">{{cite journal| author=Couser WG| title=Pathogenesis of glomerular damage in glomerulonephritis. | journal=Nephrol Dial Transplant | year= 1998 | volume= 13 Suppl 1 | issue=  | pages= 10-5 | pmid=9507491 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9507491  }} </ref>.


* Atleast 50% reduction in [[Glomerular filtration rate|GFR]] occurs in RPGN in a few days to weeks.
* Atleast 50% reduction in [[Glomerular filtration rate|GFR]] occurs in RPGN in a few days to weeks.
Line 25: Line 27:


====== Cresent formation ======
====== Cresent formation ======
* Crescents are defined as 2 or more layers of proliferating cells in the [[Bowman's capsule|Bowman's space.]]
* Crescents are defined as 2 or more layers of proliferating cells in the [[Bowman's capsule|Bowman's space.]]<ref name="pmid9507491">{{cite journal| author=Couser WG| title=Pathogenesis of glomerular damage in glomerulonephritis. | journal=Nephrol Dial Transplant | year= 1998 | volume= 13 Suppl 1 | issue=  | pages= 10-5 | pmid=9507491 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9507491  }} </ref><ref name="pmid7205449">{{cite journal| author=Roy S, Murphy WM, Arant BS| title=Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care. | journal=J Pediatr | year= 1981 | volume= 98 | issue= 3 | pages= 403-10 | pmid=7205449 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7205449  }} </ref><ref name="pmid8959617">{{cite journal| author=Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY| title=Modulators of crescentic glomerulonephritis. | journal=J Am Soc Nephrol | year= 1996 | volume= 7 | issue= 11 | pages= 2271-8 | pmid=8959617 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8959617  }} </ref>
* The crescents are made up of [[Epithelium|epithelial cells]] and macrophages which undergo [[fibrosis]].
* The crescents are made up of [[Epithelium|epithelial cells]] and macrophages which undergo [[fibrosis]]<ref name="pmid16105041">{{cite journal| author=Bariéty J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C| title=Podocyte involvement in human immune crescentic glomerulonephritis. | journal=Kidney Int | year= 2005 | volume= 68 | issue= 3 | pages= 1109-19 | pmid=16105041 | doi=10.1111/j.1523-1755.2005.00503.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16105041  }} </ref><ref name="pmid16155400">{{cite journal| author=Tipping PG, Timoshanko J| title=Contributions of intrinsic renal cells to crescentic glomerulonephritis. | journal=Nephron Exp Nephrol | year= 2005 | volume= 101 | issue= 4 | pages= e173-8 | pmid=16155400 | doi=10.1159/000088165 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16155400  }} </ref>.
* Crescents are formed after a severe injury to the [[glomerulus]].
* Crescents are formed after a severe injury to the [[glomerulus]].
* Injury to the glomerulus causes leakage of cells(epithelial[[Macrophages|, macrophages]], [[Coagulation|coagulation proteins]] and [[Fibroblast|fibroblasts]]) and [[Cytokine|cytokines]]([[Interleukin 12|IL-12]], [[Tumor necrosis factor-alpha|TNF-alpha]]) into the [[Bowman's capsule|Bowmans space]].
* Injury to the glomerulus causes leakage of cells(epithelial[[Macrophages|, macrophages]], [[Coagulation|coagulation proteins]] and [[Fibroblast|fibroblasts]]) and [[Cytokine|cytokines]]([[Interleukin 12|IL-12]], [[Tumor necrosis factor-alpha|TNF-alpha]]) into the [[Bowman's capsule|Bowmans space]].
Line 40: Line 42:
* These can be produced due to genetic causes such as in [[Goodpasture syndrome]] or they can be produced after viral [[Upper respiratory tract infection|URTI]] or cigarette smoking.
* These can be produced due to genetic causes such as in [[Goodpasture syndrome]] or they can be produced after viral [[Upper respiratory tract infection|URTI]] or cigarette smoking.
* These autoantibodies react with the GBM resulting in [[Immunoglobulin G|IgG]] deposition over the GBM.
* These autoantibodies react with the GBM resulting in [[Immunoglobulin G|IgG]] deposition over the GBM.
* The IgG activates [[T helper cell|helper T cells]] that attract the [[Inflammation|inflammatory]] mediators to the GBM damaging the glomeruli.
* The IgG activates [[T helper cell|helper T cells]] that attract the [[Inflammation|inflammatory]] mediators to the GBM damaging the glomeruli<ref name="pmid9218836">{{cite journal| author=Huang XR, Tipping PG, Apostolopoulos J, Oettinger C, D'Souza M, Milton G et al.| title=Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. | journal=Clin Exp Immunol | year= 1997 | volume= 109 | issue= 1 | pages= 134-42 | pmid=9218836 | doi= | pmc=1904710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9218836  }} </ref>.
* This damage causes leakage of cells and inflammatory mediators  resulting in crescent formation.
* This damage causes leakage of cells and inflammatory mediators  resulting in crescent formation.
* The anti GBM antibodies can affect the lungs as well as in [[Goodpasture syndrome]] resulting in glomerular [[necrosis]] and pulmonary [[Bleeding|haemorrhages]].
* The anti GBM antibodies can affect the lungs as well as in [[Goodpasture syndrome]] resulting in glomerular [[necrosis]] and pulmonary [[Bleeding|haemorrhages]].
2. [[Immune complex]]- Type II RPGN
2. [[Immune complex]]- Type II RPGN
* Immune complexes are formed in certain infections, [[Connective tissue disease|connective tissue diseases]], side effects of some drugs and in some [[Myeloproliferative neoplasm|myeloproliferative]] disorders.
* Immune complexes are formed in certain infections, [[Connective tissue disease|connective tissue diseases]], side effects of some drugs and in some [[Myeloproliferative neoplasm|myeloproliferative]] disorders<ref name="pmid17164315">{{cite journal| author=Izzedine H, Camous L, Deray G| title=New insight on crescentic glomerulonephritis. | journal=Nephrol Dial Transplant | year= 2007 | volume= 22 | issue= 5 | pages= 1480-1 | pmid=17164315 | doi=10.1093/ndt/gfl742 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17164315  }} </ref>.
* These immune complexes are deposited over the GBM.
* These immune complexes are deposited over the GBM.
* The immune complexes activate the [[complement]] system which sets off the inflammatory process.
* The immune complexes activate the [[complement]] system which sets off the inflammatory process.
Line 56: Line 58:
** [[Lupus nephritis]]
** [[Lupus nephritis]]
** [[Henoch-Schönlein purpura|Henoch-Schönlein purpural]])
** [[Henoch-Schönlein purpura|Henoch-Schönlein purpural]])
** [[IgA nephropathy|Immunoglobulin A nephropathy]]
** [[IgA nephropathy|Immunoglobulin A nephropathy]]<ref name="pmid25018935">{{cite journal| author=| title=Chapter 10: Immunoglobulin A nephropathy. | journal=Kidney Int Suppl (2011) | year= 2012 | volume= 2 | issue= 2 | pages= 209-217 | pmid=25018935 | doi=10.1038/kisup.2012.23 | pmc=4089745 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25018935  }} </ref>
** Mixed [[cryoglobulinemia]]
** Mixed [[cryoglobulinemia]]
** [[Membranoproliferative glomerulonephritis]]       
** [[Membranoproliferative glomerulonephritis]]       
Line 62: Line 64:
* No circulating [[Immune complex|immune complexes]] or [[antibodies]].
* No circulating [[Immune complex|immune complexes]] or [[antibodies]].
* Glomerular damage is caused by circulating [[Antinuclear antibodies|ANCAs]](anti nuclear cytoplasmic antibodies) or it can be idiopathic(non ANCA).
* Glomerular damage is caused by circulating [[Antinuclear antibodies|ANCAs]](anti nuclear cytoplasmic antibodies) or it can be idiopathic(non ANCA).
* ANCAs cause glomerular damage by releasing lytic enzymes from white blood cells such as [[Neutrophil|neutrophils]].
* ANCAs cause glomerular damage by releasing lytic enzymes from white blood cells such as [[Neutrophil|neutrophils]]<ref name="pmid8909258">{{cite journal| author=Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ et al.| title=Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. | journal=Am J Pathol | year= 1996 | volume= 149 | issue= 5 | pages= 1695-706 | pmid=8909258 | doi= | pmc=1865281 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8909258  }} </ref><ref name="pmid15960143">{{cite journal| author=Yang G, Tang Z, Chen Y, Zeng C, Chen H, Liu Z et al.| title=Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis. | journal=Clin Nephrol | year= 2005 | volume= 63 | issue= 6 | pages= 423-8 | pmid=15960143 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15960143  }} </ref><ref name="pmid16825335">{{cite journal| author=de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N et al.| title=Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. | journal=J Am Soc Nephrol | year= 2006 | volume= 17 | issue= 8 | pages= 2264-74 | pmid=16825335 | doi=10.1681/ASN.2005080870 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16825335  }} </ref><ref name="pmid21160463">{{cite journal| author=Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B et al.| title=ANCA-associated glomerulonephritis in the very elderly. | journal=Kidney Int | year= 2011 | volume= 79 | issue= 7 | pages= 757-64 | pmid=21160463 | doi=10.1038/ki.2010.489 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21160463  }} </ref>.
* These lytic enzymes damage the GBM and cause leakage of circulating cells and initiate crescent formationin the Bowmans space.
* These lytic enzymes damage the GBM and cause leakage of circulating cells and initiate crescent formationin the Bowmans space.
* ANCAs are associated with systemic [[Vasculitis|vasculitis.]]
* ANCAs are associated with systemic [[Vasculitis|vasculitis.]]<ref name="pmid17215440">{{cite journal| author=Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY| title=Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis. | journal=J Am Soc Nephrol | year= 2007 | volume= 18 | issue= 2 | pages= 599-605 | pmid=17215440 | doi=10.1681/ASN.2006091021 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17215440  }} </ref>
*  Examples include
*  Examples include
** [[Granulomatosis with polyangiitis]] (Wegener granulomatosis)
** [[Granulomatosis with polyangiitis]] (Wegener granulomatosis)
Line 71: Line 73:
** [[Langerhans cell histiocytosis|Eosinophilic granulomatosis]] with polyangiitis (EGPA; Churg-Strauss syndrome)
** [[Langerhans cell histiocytosis|Eosinophilic granulomatosis]] with polyangiitis (EGPA; Churg-Strauss syndrome)
** Drugs- [[hydralazine]], [[allopurinol]] and [[rifampin]].
** Drugs- [[hydralazine]], [[allopurinol]] and [[rifampin]].
==Associated Conditions==
Consitions associated with membranous glomerulonephritis include:<ref name="pmid10495797">{{cite journal |vauthors=Wasserstein AG |title=Membranous glomerulonephritis |journal=J. Am. Soc. Nephrol. |volume=8 |issue=4 |pages=664–74 |date=April 1997 |pmid=10495797 |doi= |url=}}</ref>
*[[Hepatitis B/History & Symptoms|Hepatitis B]]
*[[Hepatitis C]]
*Congenital [[Syphilis]]
*[[SLE|Systemic Lupus Erythematosis]]
*Malignancy
**[[Lung]]
**[[Breast]]
**[[Colon]]
**[[Stomach]]
**[[Kidney]]
**[[Leukemia]]
**[[Lymphomas]] ([[Hodgkin]]’s and [[non-Hodgkin]]’s)


== Gross pathology ==
== Gross pathology ==
Line 80: Line 97:


=== Histopathology ===
=== Histopathology ===
* [[Glomerular disease|Glomerular inflammation]] with signs of necrosis are present.  
* [[Glomerular disease|Glomerular inflammation]] with signs of necrosis are present<ref name="pmid20616173">{{cite journal| author=Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K et al.| title=Histopathologic classification of ANCA-associated glomerulonephritis. | journal=J Am Soc Nephrol | year= 2010 | volume= 21 | issue= 10 | pages= 1628-36 | pmid=20616173 | doi=10.1681/ASN.2010050477 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20616173  }} </ref><ref name="pmid3392885">{{cite journal| author=Bonsib SM| title=Glomerular basement membrane necrosis and crescent organization. | journal=Kidney Int | year= 1988 | volume= 33 | issue= 5 | pages= 966-74 | pmid=3392885 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3392885  }} </ref>.  
* .Glomerular caplillary wall rupture and damage to GBM.
* .Glomerular caplillary wall rupture and damage to GBM.
* Crescents are present in the [[Bowman's capsule|Bowmans space]].
* Crescents are present in the [[Bowman's capsule|Bowmans space]].
Line 89: Line 106:
* [[Tubular]] necrosis may also be present.
* [[Tubular]] necrosis may also be present.
* Interstitial [[Granuloma|granulomas]] in the glomeruli indicate [[Granulomatosis with polyangiitis|Wegener’s granulomatosis]].
* Interstitial [[Granuloma|granulomas]] in the glomeruli indicate [[Granulomatosis with polyangiitis|Wegener’s granulomatosis]].
[[Image:Post-rapidly progressive glomerulonephritis - very high mag (1).jpg|200px|centre|Source:By Nephron - Own work<ref/ https://commons.wikimedia.org/w/index.php?curid=17591464 ref>>]]
[[File:192px-Crescentic glomerulonephritis (1).jpg|200px|center|thumb| Microscopic findings of RPGN Source:By Nephron - Own work<ref> https://commons.wikimedia.org/w/index.php?curid=17591464 </ref>]]
 
 


=== Immunoflourescence ===
=== Immunoflourescence ===
Line 103: Line 118:


== Genetics ==
== Genetics ==
People with [[Human leukocyte antigen|HLA]] DP1,DQ and DRB4 are more susceptible to develop RPGN.
People with [[Human leukocyte antigen|HLA]] DP1,DQ and DRB4 are more susceptible to develop RPGN<ref name="pmid15652778">{{cite journal| author=Jagiello P, Gross WL, Epplen JT| title=Complex genetics of Wegener granulomatosis. | journal=Autoimmun Rev | year= 2005 | volume= 4 | issue= 1 | pages= 42-7 | pmid=15652778 | doi=10.1016/j.autrev.2004.06.003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15652778  }} </ref>.
{{#ev:youtube|CqSyj4cVZPE}}
{{#ev:youtube|CqSyj4cVZPE}}


Latest revision as of 18:43, 31 July 2018

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis pathophysiology

CDC on Rapidly progressive glomerulonephritis pathophysiology

Rapidly progressive glomerulonephritis pathophysiology in the news

Blogs on Rapidly progressive glomerulonephritis pathophysiology

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis pathophysiology

.Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2] Syed Ahsan Hussain, M.D.[3]

Overview

Rapidly progressive glomerulonephritis is a disease of the kidney in which the renal function deteriorates in a few days. Atleast 50% reduction in GFR occurs in RPGN in a few days to weeks. RPGN occurs from severe and fast damage to the GBM which results in crescent formation, the main pathological finding in RPGN. Injury can occur by anti GBM antibodies-type I RPGN, Immune complex- type II RPGN or pauci immune RPGN(ANCAs)-type III RPGN. Crescents are present in the Bowmans space. Light, immunofluoresnce and electron microscopy are used to diagnose RPGN.

Pathophysiology

Anatomy

Renal corpuscle. (Source: [Michal Komorniczak (Poland)[CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)], from Wikimedia Commons])
Alveolar wall ([By Cruithne9 [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)], from Wikimedia Commons])


The key for the renal corpuscle figure is: A – Renal corpuscle, B – Proximal tubule, C – Distal convoluted tubule, D – Juxtaglomerular apparatus, 1. Basement membrane (Basal lamina), 2. Bowman's capsule – parietal layer, 3. Bowman's capsule – visceral layer, 3a. Pedicels (Foot processes from podocytes), 3b. Podocyte, 4. Bowman's space (urinary space), 5a. Mesangium – Intraglomerular cell, 5b. Mesangium – Extraglomerular cell, 6. Granular cells (Juxtaglomerular cells), 7. Macula densa, 8. Myocytes (smooth muscle), 9. Afferent arteriole, 10. Glomerulus Capillaries, 11. Efferent arteriole.

Pathogenesis

  • Rapidly progressive glomerulonephritis is a disease of the kidney in which the renal function deteriorates in a few days[1][2].
  • Atleast 50% reduction in GFR occurs in RPGN in a few days to weeks.
  • RPGN occurs from severe and fast damage to the GBM which results in crescent formation, the main pathological finding in RPGN.
  • The injury to GBM can be caused by multiple factors.
  • Crescent formation is the major pathological finding.
  • In some cases crescents might be absent.
Cresent formation
Glomerular injury
  • Injury to the glomerulus is the initiating factor for crescent formation.
  • Injury can occur by the following.
  1. Anti GBM antibodies-Type I RPGN
  • These are autoantibodies that cross react with type IV collagen of the GBM.
  • These can be produced due to genetic causes such as in Goodpasture syndrome or they can be produced after viral URTI or cigarette smoking.
  • These autoantibodies react with the GBM resulting in IgG deposition over the GBM.
  • The IgG activates helper T cells that attract the inflammatory mediators to the GBM damaging the glomeruli[7].
  • This damage causes leakage of cells and inflammatory mediators resulting in crescent formation.
  • The anti GBM antibodies can affect the lungs as well as in Goodpasture syndrome resulting in glomerular necrosis and pulmonary haemorrhages.

2. Immune complex- Type II RPGN

  • Immune complexes are formed in certain infections, connective tissue diseases, side effects of some drugs and in some myeloproliferative disorders[8].
  • These immune complexes are deposited over the GBM.
  • The immune complexes activate the complement system which sets off the inflammatory process.
  • The complement cascade is activated, attracting inflammatory cells and mediators to the GBM.
  • The serum levels of c3 and c4 fall down and is an indicator of immune complex mediated glomerular injury.

3. Pauci immune RPGN-Type III RPGN

Associated Conditions

Consitions associated with membranous glomerulonephritis include:[15]

Gross pathology

Microscopic pathology

Histopathology

Microscopic findings of RPGN Source:By Nephron - Own work[18]

Immunoflourescence

  • In type I RPGN- diffuse and linear deposition of IgG along the GBM.
  • In ttype II RPGN- diffuse and irregular deposition of IgG and C3 in the mesangial matrix.
  • In type III RPGN- no finding.

Electron microscopy

  • In type I and type III, no electron dense deposits are seen.
  • In type II RPGN, subepithelial electron dense deposits indiacting the presence of immune complexes are seen.

Genetics

People with HLA DP1,DQ and DRB4 are more susceptible to develop RPGN[19]. {{#ev:youtube|CqSyj4cVZPE}}

References

  1. ↑ Couser WG (1988). "Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy". Am J Kidney Dis. 11 (6): 449–64. PMID 3287904.
  2. ↑ 2.0 2.1 Couser WG (1998). "Pathogenesis of glomerular damage in glomerulonephritis". Nephrol Dial Transplant. 13 Suppl 1: 10–5. PMID 9507491.
  3. ↑ Roy S, Murphy WM, Arant BS (1981). "Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care". J Pediatr. 98 (3): 403–10. PMID 7205449.
  4. ↑ Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY (1996). "Modulators of crescentic glomerulonephritis". J Am Soc Nephrol. 7 (11): 2271–8. PMID 8959617.
  5. ↑ Bariéty J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C (2005). "Podocyte involvement in human immune crescentic glomerulonephritis". Kidney Int. 68 (3): 1109–19. doi:10.1111/j.1523-1755.2005.00503.x. PMID 16105041.
  6. ↑ Tipping PG, Timoshanko J (2005). "Contributions of intrinsic renal cells to crescentic glomerulonephritis". Nephron Exp Nephrol. 101 (4): e173–8. doi:10.1159/000088165. PMID 16155400.
  7. ↑ Huang XR, Tipping PG, Apostolopoulos J, Oettinger C, D'Souza M, Milton G; et al. (1997). "Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats". Clin Exp Immunol. 109 (1): 134–42. PMC 1904710. PMID 9218836.
  8. ↑ Izzedine H, Camous L, Deray G (2007). "New insight on crescentic glomerulonephritis". Nephrol Dial Transplant. 22 (5): 1480–1. doi:10.1093/ndt/gfl742. PMID 17164315.
  9. ↑ "Chapter 10: Immunoglobulin A nephropathy". Kidney Int Suppl (2011). 2 (2): 209–217. 2012. doi:10.1038/kisup.2012.23. PMC 4089745. PMID 25018935.
  10. ↑ Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ; et al. (1996). "Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat". Am J Pathol. 149 (5): 1695–706. PMC 1865281. PMID 8909258.
  11. ↑ Yang G, Tang Z, Chen Y, Zeng C, Chen H, Liu Z; et al. (2005). "Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis". Clin Nephrol. 63 (6): 423–8. PMID 15960143.
  12. ↑ de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N; et al. (2006). "Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement". J Am Soc Nephrol. 17 (8): 2264–74. doi:10.1681/ASN.2005080870. PMID 16825335.
  13. ↑ Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B; et al. (2011). "ANCA-associated glomerulonephritis in the very elderly". Kidney Int. 79 (7): 757–64. doi:10.1038/ki.2010.489. PMID 21160463.
  14. ↑ Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY (2007). "Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis". J Am Soc Nephrol. 18 (2): 599–605. doi:10.1681/ASN.2006091021. PMID 17215440.
  15. ↑ Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
  16. ↑ Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K; et al. (2010). "Histopathologic classification of ANCA-associated glomerulonephritis". J Am Soc Nephrol. 21 (10): 1628–36. doi:10.1681/ASN.2010050477. PMID 20616173.
  17. ↑ Bonsib SM (1988). "Glomerular basement membrane necrosis and crescent organization". Kidney Int. 33 (5): 966–74. PMID 3392885.
  18. ↑ https://commons.wikimedia.org/w/index.php?curid=17591464
  19. ↑ Jagiello P, Gross WL, Epplen JT (2005). "Complex genetics of Wegener granulomatosis". Autoimmun Rev. 4 (1): 42–7. doi:10.1016/j.autrev.2004.06.003. PMID 15652778.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Rapidly_progressive_glomerulonephritis_pathophysiology&oldid=1487006"